A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Risankizumab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 30 Oct 2017 Planned End Date changed from 16 Sep 2021 to 3 Sep 2021.
- 30 Oct 2017 Planned initiation date changed from 4 Jun 2018 to 22 May 2018.
- 20 Jul 2017 New trial record